Vasculitis Drug Market
Global Vasculitis Drug Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Immunosuppressants, and Biologics), By Disease Type (Small Vessel, Large Vessel, and Medium Vessel Vasculitis) By End-User (Hospitals, Medical Clinics, Others), Forecast Period, 2022-2028
The global vasculitis drug market is projected to grow at a significant CAGR during the forecast period (2022-2028). Vasculitis is a medical condition in which the blood vessels in the skin, eyes, brain, or other internal organs become inflamed. Fatigue, weakness, weight loss, muscular aches, heart failure, depression, and other symptoms are common. Medications such as corticosteroids and cytotoxic medicines are among the several treatments.
It can also happen as a result of an infection, medication, or other illnesses and symptoms include fatigue, weakness, weight loss, muscle pain, heart failure, depression, and more. The global spread of chronic diseases is a primary driver of market expansion. Inflammation of the blood vessels can be caused by autoimmune disorders, trauma, and various illnesses, among other things. As a result, the market's growth is accelerated by the increasing prevalence of these illnesses.
Impact of COVID-19 on Global Vasculitis Drug Market
COVID-19 has a positive impact on the growth of the global vasculitis drug market. The pandemic has created opportunities and challenges for the companies operating in the healthcare ecosystem. The COVID-19 pandemic in the major economies has disrupted manufacturing and transportation. However, it has generated challenges for the treatment of people suffering from vasculitis drugs. In addition, growing concern about the risk of infection and the decline in socio-economic conditions reduce the cost of public health care worldwide. The number of patients in the hospitals has increased due to the COVID-19 virus, which has forced the countries to increase healthcare expenditure.
Segmental Outlook
The global vasculitis drug market is segmented based on drugs class, disease type, and end-user. Based on the drug class segment, the market is sub-segmented into corticosteroids, immunosuppressants, and biologics. Based on disease type segment, the market sub-segmented into a small vessel, large vessel, and medium vessel vasculitis. Based on the end-user segment, the market is sub-segmented into hospitals medical clinics, and others. Among the drug, the corticosteroids segment is anticipated to propel the growth of the market over the forecast period, owing to the rising inclination of the population towards the vasculitis drug.
Global Vasculitis Drug Market Share by Drug, 2021 (%)
The Corticosteroids is Anticipated to Hold a Prominent Share in the Global Vasculitis Drug Market
Based on the drug segment the market is sub-segmented into corticosteroids, immunosuppressants, and biologics. Among the drug, the corticosteroids segment is anticipated to hold prominent share in the market during the forecast period, owing to the rising inclination of the population towards the vasculitis drug. Prednisone is the most common form of corticosteroid used to treat vasculitis-related inflammation. It is one of the fastest-acting glucocorticoids used to treat all types of vasculitis. Prednisone is usually prescribed depending on the kind of vasculitis and its severity. Methylprednisolone is also used to treat ANCA (AAV)-related vasculitis in patients. ChemoCentryx, Inc., suggested to the US Food and Drug Administration (FDA) in July 2020 to submit a new drug application (NDA) for corticosteroids to provide effective treatment for persons with ANCA-related vasculitis. This will reduce the toxicity associated with daily steroid administration, resulting in better patient outcomes.
Regional Outlook
The global vasculitis drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is projected to hold a significant market share. China, India, Japan, and the Rest of the Asia-Pacific are the major economies primarily contributing to the growth of the Vasculitis drug market in the region. The vasculitis drug market can be analyzed for a particular region or country level as per the requirement. The Asia-Pacific regional bio-implants market is expected to hold a prominent market share owing to lucrative market opportunities for market players.
Global Vasculitis Drug Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Considerable Share in the Global Vasculitis Drug Market
Asia-Pacific region holds the major share and is anticipated to grow fastest during the forecast period in the vasculitis drug market. The attributable factor for the growth of the market in the region is the increase in the number of trauma cases and serious road accidents in India. The Asia-Pacific region is expected to present significant market growth opportunities. Increased public health awareness is likely to drive regional market growth. In addition, growing cases of microscopic polyangiitis (MPA) in this region especially in China and Japan have an significant impact on the market. In addition, rising health care costs and increased government efforts to treat vasculitis also contribute to market growth.
Market Players Outlook
Some major players in the market include GlaxoSmithKline plc, F. Hoffmann-La Roche AG, and Novartis International AG, among others. Market players make a significant contribution to market growth through the adoption of a variety of strategies including integration and acquisition, expansion of partnerships, partnerships, and the introduction of new products, to stay competitive in the market. For instance, in July 2020, AbbVie Inc. had set forth RINVOQ that is considered to be continuously evaluated across multiple inflammatory diseases for effective outcomes, RINOQ is a prescription medicine.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global vasculitis drug market.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Vasculitis Drug Market
• Recovery Scenario of Global Vasculitis Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. F. Hoffmann-La Roche AG
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. GlaxoSmithKline plc
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Novartis International AG
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Pfizer Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
4. Market Segmentation
4.1. Global Vasculitis Drug Market by Drug Class
4.1.1. Corticosteroids
4.1.2. Immunosuppressants
4.1.3. Biologics
4.2. Global Vasculitis Drug Market by End-User
4.2.1. Hospitals
4.2.2. Medical Clinics
4.2.3. Others
4.3. Global Vasculitis Drug Market by Disease Type
4.3.1. Small Vessel
4.3.2. Large Vessel
4.3.3. Medium Vessel
5. Regional Analysis
5.1. North America
5.1.1. The United States
5.1.2. Canada
5.2. Europe
5.2.1. The UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.
6.2. Amgen Inc.
6.3. Bristol-Myers Squibb Co.
6.4. ChemoCentryx, Inc.
6.5. Celltrion Healthcare Co. Ltd.
6.6. Johnson & Johnson Service Co.
6.7. Merck & Co., Inc.
6.8. Mentor Worldwide LLC
6.9. Teva Pharmaceuticals
6.10. Sun Pharma
6.11. Sanofi SA
6.12. Pfizer
1. GLOBAL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028($ MILLION)
2. GLOBAL CORTICOSTEROIDSVASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
3. GLOBAL IMMUNOSUPPRESSANTS VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
4. GLOBAL BIOLOGICS VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
5. GLOBAL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY END-USE, 2021-2028($ MILLION)
6. GLOBAL HOSPITALS VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
7. GLOBAL MEDICAL CLINICS VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
8. GLOBAL OTHERS VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
9. GLOBAL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028($ MILLION)
10. GLOBAL SAMLL VESSEL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
11. GLOBAL MEDIUM VESSEL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
12. GLOBAL LARGE VESSEL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
13. GLOBAL VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028($ MILLION)
14. NORTH AMERICAN VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028($ MILLION)
15. NORTH AMERICAN PORTABLE BLENDERS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028($ MILLION)
16. NORTH AMERICAN PORTABLE BLENDERS MARKET RESEARCH AND ANALYSIS BY END-USE, 2021-2028($ MILLION)
17. NORTH AMERICAN PORTABLE BLENDERS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028($ MILLION)
18. EUROPEAN VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028($ MILLION)
19. EUROPEAN VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028($ MILLION)
20. EUROPEAN VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY END-USE, 2021-2028($ MILLION)
21. EUROPEAN VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028($ MILLION)
22. ASIA-PACIFIC VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028($ MILLION)
23. ASIA-PACIFIC VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028($ MILLION)
24. ASIA-PACIFIC VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY END-USE, 2021-2028($ MILLION)
25. ASIA-PACIFIC VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028($ MILLION)
26. REST OF THE WORLD VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028($ MILLION)
27. REST OF THE WORLD VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028($ MILLION)
28. REST OF THE WORLD VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY END-USE, 2021-2028($ MILLION)
29. REST OF THE WORLD VASCULITIS DRUG MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2021-2028($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL VASCULITIS DRUG MARKET, 2021-2028($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL VASCULITIS DRUG MARKET BY SEGMENT, 2021-2028($ MILLION)
3. RECOVERY OF GLOBAL VASCULITIS DRUG MARKET, 2021-2028(%)
4. GLOBAL VASCULITIS DRUG MARKET SHARE BY DRUG CLASS, 2021 VS 2028(%)
5. GLOBAL CORTICOSTEROIDS VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
6. GLOBAL IMMUNOSUPPRESSANTS VASCULITIS DRUG MARKET SHARE, 2021 VS 2028(%)
7. GLOBAL BIOLOGICS VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
8. GLOBAL VASCULITIS DRUG MARKET SHARE BY END-USE, 2021 VS 2028(%)
9. GLOBAL HOSPITALS VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
10. GLOBAL MEDICAL CLINICS VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
11. GLOBAL OTHERS VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
12. GLOBAL VASCULITIS DRUG MARKET SHARE BY DISEASE TYPE, 2021 VS 2028(%)
13. GLOBAL SMALL VESSEL VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
14. GLOBAL MEDIUM VESSEL VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
15. GLOBAL LARGE VESSEL VASCULITIS DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028(%)
16. US VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
17. CANADA VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
18. UK VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
19. FRANCE VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
20. GERMANY VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
21. ITALY VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
22. SPAIN VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
23. REST OF EUROPE VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
24. INDIA VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
25. CHINA VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
26. JAPAN VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
27. SOUTH KOREA VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
28. REST OF ASIA-PACIFIC VASCULITIS DRUG MARKET SIZE, 2021-2028($ MILLION)
